KBP Biosciences is a global, clinical stage biopharmaceutical company focused on the development of an
innovative pipeline of new chemical entities with known mechanisms of action targeting underserved
patient populationsin organ protection and infectious diseases.
KBP utilizes an integrated discovery and development platform that enables the Company
to efficiently bring new therapies from bench to patients around the world.
Our lead product candidate, KBP-5074, is a third-generation non-steroidal mineralocorticoid receptor
antagonist (MRA) with a potentially best-in-class safety and efficacy profile. It is in clinical development for
the treatment of uncontrolled hypertension and cardiorenal disease in stage 3b/4 Chronic
Kidney Disease (CKD) patients who have high risk of hyperkalemia.
At KBP Biosciences we are dedicated to push the boundaries of science to transform the lives patients around the world.
We are dedicated to delivering value to our communities, our employees, and the environment.
We are responsible for our actions on people and the planet. We are also mindful of our social responsibilities,
and committed to high standards of governance.
;){kind=link}
, medical services (Arrail Dental), medical devices (HealForce), precision medicine (Genetron Health) and mobile health (WiwideYoukang). Before joining New Horizon, Dr. Qiu led transactions for Kangning Hospitals Group (HKSE:2120) and Arrail Dental, as a key member of a healthcare dedicated private equity fund – GL Capital.</p><p>As one of the founding members of the Healthcare Advisory team at PwC China, Dr. Qiu built up a client base including big pharma companies and investment firms, providing strategy, operational improvement consulting and due diligence services. He started his healthcare career by working with the Vancouver General Hospital as an analyst/project leader. Dr. Qiu graduated from the University of British Columbia with an M.B.A. in Finance, and Eastern China University of Technology with a bachelor’s degree in power engineering. Dr. Qiu also holds his Chartered Finance Analyst and Certified Management Accountant designations.</p>');){kind=link}
, NKF K/DOQI, and the American Diabetes Association Practice Guideline Committee (2002-2004).</p><p>Dr. Bakris is a member of numerous national committees and professional societies, and serves on many of their advisory boards, including those of the American Diabetes Association, American Society of Nephrology, the ISHIB, and the NKF. He is Past President of the American College of Clinical Pharmacology. Dr. Bakris currently serves on 14 editorial boards, including those of the American Journal of Hypertension, American Journal of Nephrology, Hypertension, and the Journal of Clinical Pharmacology and Ethnicity & Disease. His research has been published in more than 200 articles.</p><p>Dr. Bakris obtained his medical training at the Rosalind Franklin University of Medicine and Science and completed is residency training at the Mayo Clinic.</p><p><br/></p>');){kind=link}
 Pitt, M.D.','Professor Emeritus, University of Michigan Medical School','<p>Dr. Pitt’s research is in cardiovascular disease, with special emphasis on the ischemic heart disease and heart failure. He spent 15 years as the Director, Division of Cardiology at University of Michigan School of Medicine. Dr. Pitt has chaired or co-chaired a number of clinical trials in cardiology including SOLVD; ELITE I and II; PREVENT; RALES; EPHESUS; and TOPCAT and has published over 500 articles in peer reviewed journals. Dr. Pitt has been a member of a numerous medical journal editorial boards and medical organizations, as well as served as an advisor to the clinical trials branch of the NHLBI and a member of the FDA cardio-renal advisory board. He has been awarded the James B. Herrick Award by the Council of Clinical Cardiology of the American Heart Association. He is Diplomate of the American Board of Internal Medicine and of the American Board of Cardiology.</p><p>Dr. Pitt is a member of numerous professional societies and has held office in several of them. Among others, he was Chairman, Council on Circulation of the American Heart Association, Chairman, Young Investigator’s Award Committee of the American College of Cardiology, and is currently Chairman of the Reveal Committee of the ACC.</p><p>Dr. Pitt received his M.D. degree from the University of Basel, Switzerland. He completed his fellowship in cardiology at the Johns Hopkins University School of Medicine.</p><p><br/></p>');){kind=link}
;){kind=link}
 where she served in preclinical and clinical disposition and metabolism moving into international regulatory affairs and business development. She served in a series of Vice President roles and supported a wide range of therapeutic areas at GSK including pulmonary, anti-infectives, oncology, cardiovascular, metabolic, urology with eleven years in vaccine development.</p><p>Dr. Kahn has a Ph.D. in Biochemical Pharmacology from the Department of Clinical Pharmacology at The Royal Postgraduate Medical School, London and moved to Philadelphia to serve as Assistant Professor in the Departments of Pharmacology and Laboratory Medicine at the University of Pennsylvania. Dr. Kahn served on the Executive Committee of the Graduate Group in Pharmacological Sciences and retained an adjunct faculty position for several years after joining industry.</p><p><br/></p>');){kind=link}
 in 1996 as Director of Research. In 2003, he joined the Collège de France in Paris as an independent INSERM team and is currently the director of a team of the INSERM Unit U1138, at the Cordeliers Research Centre, Paris. Between 2010-2015, he was Scientific Delegate of the Pathophysiology Committee of the French National Research Agency. He has been recently appointed as French coordinator for Life Sciences in the ECOS French-South America exchange program.</p><p>The aim of his current studies is to improve the understanding of the pathophysiological roles and signaling pathways whereby the hormone aldosterone promotes pathologies in various organs including the kidney and the cardiovascular system. His work combines cellular and molecular approaches, animal physiology, pharmacological studies and has implications in human diseases. His interest includes translational research aimed to identify and validate biomarkers of mineralocorticoid receptor activation in cardiovascular and kidney diseases and novel therapeutic use of MR antagonists. He published 100 papers (H index 33, 2800 citations). Dr. Jaisser received his medical training and degrees from the Reims Medical School and was qualified as Nephrologist in 1990.</p><p><br/></p>');){kind=link}
 Disease at the Brigham and Women’s Hospital, Boston, Massachusetts, and visiting Professor of Medicine, Harvard University, Boston, in 2010/2011. He is also Past-President of the Heart Failure Association of the European Society of Cardiology (ESC).</p><p>Professor McMurray’s primary research interest is in heart failure (HF) and his main research activity is clinical trials. He is, or was, the principal investigator, and member of the executive committee or steering committee in a number of large trials in HF, other CV diseases, renal disease and diabetes.</p><p>Professor McMurray sits on the editorial board of the New England Journal of Medicine. He has published approximately 600 original papers, reviews, and book chapters and was the lead author of the World Health Organization and first Scottish Intercollegiate Guidelines Network Guidelines on the Management of HF. In addition, he was Co-Chair of the Kidney Disease Improving Global Outcomes Anemia Guidelines Committee; and member of the 2013 American College of Cardiology/American Heart Association HF Guidelines Committee. He is a member of the National Institute for Health and Care Excellence (NICE) Acute HF Guidelines Committee and was recently appointed to NICE (Appraisal Committee A). Professor McMurray was included in the 2014 listing of Highly Cited Researchers by Thomson-Reuters.</p><p><br/></p>');){kind=link}
 and the Infectious Diseases Society of America (IDSA) committee which developed guideline statements on hospital-acquired and healthcare-associated pneumonia and currently serves on the ERS/ ESCIM/ ESCMID/ ALAT Guidelines for the management of Hospital acquired pneumonia. </p>');){kind=link}
 and FIBROTARGETS (fibrosis as a biotargets [www.fibrotargets.eu]). As the primary investigator or member of the oversight committees in major clinical trials, Professor Zannad has made significant contributions to evidence‐based heart failure life‐saving therapy, mainly with beta‐blockers (CIBIS) and mineralocorticoid receptor antagonists (RALES, EPHESUS, EMPHASIS‐HF). He pioneered cardiovascular outcome trials in chronic kidney disease (FOSIDIAL, AURORA, ALCHEMIST) and the one of the first cardiovascular safety trials on glucose‐lowering drugs in diabetes (EXAMINE). Professor Zannad has served as Chairman of the French Society of Hypertension, Chairman of the ESC Working Group on pharmacology and drug therapy, and board member of the ESC Heart Failure Association. He was Founder and is currently Chairman of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, an annual international meeting dedicated to the science of clinical trials, and of the International Workshop on Biomarkers in heart failure. As of July 2016, Professor Zannad has authored more than 530 scientific publications.</p><p>He earned his M.D. degree and cardiology specialty at the University of Lorraine in 1979 and his PhD degree in clinical pharmacology at the University of Lyon in Lyon, France, in 1984; during his PhD study, he also completed a fellowship at the MRC Clinical Pharmacology unit, Oxford, UK. Professor Zannad is currently Head of the Division of Heart Failure and Hypertension and Director of the Inserm Clinical Investigation Center at “Institut Lorrain du Coeur et des Vaisseaux” in the Centre Hospitalier et Universitaire of Nancy.</p><p><br/></p>');){kind=link}
;){kind=link}